Citations 0
Editor's Correspondence
April 12, 1999

Problems With Measuring the Use of β-Blockers in Ambulatory Settings for Secondary Prevention in Patients With Coronary Artery Disease

Author Affiliations

Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

Arch Intern Med. 1999;159(7):755-756. doi:

We read the article by Wang and Stafford1 regarding the underuse of β-blockers in patients with coronary artery disease for secondary prevention and would like to comment on the reasons why β-blockers may have been underprescribed. Only 5.5% of the study patients had a history of myocardial infarction. The data for using β-blockers as secondary prophylaxis for those without a history of myocardial infarction are not as strong as for those with a history of myocardial infarction as these authors themselves conclude: " β-Blocker therapy should probably not be limited to those patients who are hospitalized for myocardial infarction."1

First Page Preview View Large
First page PDF preview
First page PDF preview